Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 07:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses...
October 25, 2025 09:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including...
October 23, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
October 06, 2025 04:24 ET | Source: Research and Markets

Barrett's Esophagus with Dysplasia Market Global and Regional Analysis 2025-2035

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Barrett's Esophagus with Dysplasia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has...
September 15, 2025 05:56 ET | Source: Research and Markets

Barrett's Esophagus Strategic Business Report 2025-2030 Featuring 34 Companies - Innovative Diagnostics and Therapies Propel Market Growth

Dublin, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The "Barrett's Esophagus - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Barrett's Esophagus...
August 25, 2025 07:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
August 07, 2025 06:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to...
July 28, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
June 16, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
June 06, 2025 12:27 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen...